|
![]() |
貨號 | 品名 | 規(guī)格 | 包裝 | 單價 | 貨期 | 庫存 |
JD200512093702 | 度伐單抗 | 99.50% | 5mg | 11400元 | 咨詢客服 | 3天 |
JD200512093642 | 度伐單抗 | 99.50% | 1mg | 5400元 | 咨詢客服 | 3天 |
性狀: | Durvalumab (MEDI 4736) 是一種人源化的抗 PD-L1 蛋白單克隆抗體。Durvalumab (MEDI 4736) 完全阻斷 PD-L1 與 PD-1 和 CD80 結(jié)合, IC50 分別為 0.1 和 0.04 nM。 |
質(zhì)量標(biāo)準(zhǔn): | Description Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody[1]. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively[2]. IC50 & Target IC50: 0.1 nM (PD-L1/PD-1), 0.04 nM (PD-L1/CD80)[2] |
貯存: | Storage Please store the product under the recommended conditions in the Certificate of Analysis. References [1]. Faiena I, et al. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. Drug Des Devel Ther. 2018 Jan 23;12:209-215. [2]. Stewart R, et al. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Cancer Immunol Res. 2015 Sep;3(9):1052-62. |